. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015 Feb 3;10(4):633-44. Epub 2015 Jan 22 PubMed.


Please login to recommend the paper.


  1. This study by Matarin et al. is, by a considerable margin, the largest microarray-based investigation of Alzheimer’s disease (AD) mouse models to date. The authors monitored and compared transcript levels of more than 12,500 genes in five AD models (plus one control mouse line) at four different ages and for three different brain regions. To my knowledge, the scale of this study is only eclipsed by one prior herculean AD-related microarray investigation, which compared gene expression patterns in three brain regions of 600 human brains (Podtelezhnikov et al., 2011). Both studies were complementary in their design and pointed toward a distortion of immune or inflammatory response gene products early in the disease.

    This kind of discovery research is urgently needed and incredibly useful, yet is also renowned for falling short on follow-up data analysis and validation, making it difficult for the reader to extract useful information. The authors avoided this trap by following their microarray tour de force with a careful bioinformatic evaluation. In particular, the network analysis of immune genes and the comparison of microarray and GWAS data sets added value and revealed useful insights. From my perspective, two interesting observations stood out: 

    1. Whereas extracellular amyloid disease primarily underlies inflammatory perturbations, the deposition of tau correlates better with changes to transcripts coding for synaptic proteins. The relationship of Aβ and tau pathologies to synaptic deficits is a matter of considerable contention in the field. It is refreshing to learn that data from a large-scale discovery approach place the blame for synaptic deficits squarely on tau. This finding contributes to understanding the basis of distinct presentations of AD and FTD-17—as also noted by the authors. 

    2. Trem2, one of the stronger risk factors for developing late-onset AD (Guerreiro et al., 2013; Jonsson  et al., 2013), may steer changes to the immune response downstream of amyloid pathology but may play a lesser role in the brain’s response to tau deposition. The proposition that a subset of the new AD risk genes that emerged in large-cohort GWAS studies, including Trem2, influence Aβ rather than tau biology is not new, but the current study makes a particularly compelling case in its favor due to the rigorous, hypothesis-free approach it pursued. 

    As with any study, there are also caveats with this work. For example, the overexpression of APP transgenes in three of the four amyloid AD mouse models investigated represents a shortcoming accentuated by the heightened awareness that non-physiological levels of non-Aβ products of APP can skew phenotypes (Saito et al., 2014). Moreover, although the study is suggestive of a scenario whereby synaptic deficits in AD are predominantly driven by tau pathology, this conclusion has to remain tentative. The systems biology that precipitates synaptic deficits may be sufficiently different when both Aβ and tau etiologies unfold together, an aspect of AD not modeled in the current study. To begin to address this question, it would be interesting to learn about differences and commonalities in the data of this and the aforementioned human AD microarray study.

    It is safe to assume that the extensive inventory of AD-related gene expression data will serve as a valuable resource that may unleash its full potential only in the years to come. As a researcher undertaking conceptually similar proteomics analyses, I certainly look forward to using this resource to look up levels of gene products which we flagged in our own AD data sets.


    . Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging. PLoS One. 2011;6(12):e29610. PubMed.

    . TREM2 variants in Alzheimer's disease. N Engl J Med. 2013 Jan 10;368(2):117-27. Epub 2012 Nov 14 PubMed.

    . Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013 Jan 10;368(2):107-16. Epub 2012 Nov 14 PubMed.

    . Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014 May;17(5):661-3. Epub 2014 Apr 13 PubMed.

  2. Thank you for your comment. I completely agree with the caveat concerning the overexpression of APP and PSEN1. We are now breeding the APPKI mice from Takaomi Saido’s group (see Saito et al., 2014) and are fully intending to add the data on these mice to mouseac.org as they come through. The comparison will be very interesting indeed. Where they show similar effects it will confirm the interpretation, but where they are different will add additional information about the role of APP itself. It is interesting to note, however, that whether heterozygous or homozygous, and whether with or without the additional PSEN1 transgene, the correlation of the immune gene expression to plaques is very close to 1:1, suggesting that it is indeed the plaques that are in the driver’s seat.


    . Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014 May;17(5):661-3. Epub 2014 Apr 13 PubMed.

  3. In this manuscript, Matarin and colleagues show, for the first time, a comparison of changes in mRNA expression with progressive pathology in different transgenic mouse models of Alzheimer’s disease. Analyses of the hippocampus, cortex, and cerebellum were performed in five mice; four driven by mutant APP and/or PS1 transgenes on thy1 promoters, and one driven by mutant tau transgene overexpression on the CaMKII promoter. This manuscript shows that the accumulation of plaques very tightly associated with an increase in expression of genes associated with immune and inflammatory responses. On the other hand, when tau was overexpressed in forebrain neurons, there was a down-regulation of genes associated with synaptic function and neurotransmitter release and transport.

    The authors also analyzed how the expression of AD risk genes previously identified by GWAS changed in these mice in order to help elucidate the value of these models of disease. Notably, changes in expression of Apoe, CD33, Inpp5d, Ms4a6d, and Trem2, were observed in some of the models, particularly in the tau and APP+PS1 lines, suggesting that these transgenic mice do in fact appropriately model at least some aspects of AD. The authors conclude from this study that targeting the accumulation of tau pathology would be most effective in abrogating the progression of memory decline associated with late stage AD pathology, since it was closely tied to suppressed expression of components vital to synaptic function, while targeting amyloid pathology could decrease activation of the immune system. These findings lend further support to the idea that Aß triggers the dysfunction in the brain, perhaps through immune activation, while tau accumulation is ultimately responsible for the neurodegeneration that leads to late-stage decline. Moreover, the authors have provided a comprehensive database that can now be used by any lab to further investigate gene expression changes in these mouse models. This database is a valuable tool for anyone working in these models.

  4. The reported finding of increased immune gene expression as an early event in transgenic Alzheimer’s disease (AD) mice models is, for several reasons, very intriguing:

    1. A major concern—frequently raised in connection with transgenic AD mice models harboring causal mutations—is their relevance to sporadic late-onset AD, which is by far the most common form of the disease. In this respect, it is noteworthy that the reported immune gene expression changes in the Aβ mice pertain to genes coding for complement factor C1q and microglia receptors, which can already be found in early stages of AD pathology in the brain. Immunohistochemical studies show that diffuse Aβ plaques, the initial neuropathological lesion, are immunolabeled for the early complement factors and that upregulation of monocyte/macrophage receptors on glia cells is seen at early stages of AD pathology, before the appearance of tau-related neuropathological changes (Eikelenboom et al., 2011). Furthermore, it is striking that the reported hub genes for early immune factors in the transgenic AD mouse models are related to genes that are genetic risk factors for the late-onset form of AD. It is intriguing to see the similarities between the early changes in the immune gene expression in transgenic AD mice models, and the genetic risk factors and pathological findings for related immune changes in the early pathological stages of AD.

    2. Matarin and co-workers discussed that their findings indicate a separate involvement of the immune system in the early and late stages of AD pathology. We found evidence for upregulation of inflammatory mediators, complement proteins, and adhesion molecules in the initial stages of AD pathology. The early brain changes associated with neuroinflammation precede the extensive process of tau pathology related to neurodegeneration (Hoozemans et al., 2006). This early neuroinflammatory response closely associates with an aberrant regenerative response that has been well studied in the past by Carl Cotman (Irvine Institute) and Thomas Arendt (Leipzig). These findings in human AD brains are in line with the findings of Matarin, which suggest that the late but not the early immune changes are closely related with the Aβ-induced neurotoxicity.

    3. Network analysis shows that upregulated gene expression of complement protein C1q belongs to the hub genes in the different models. Immunohistochemical studies of the AD brain have shown that amyloid plaques contain the early complement factors C1q, C4, and C3, as well as late complement factors including the lytic membrane attack complex. It is generally thought that these complement factors are involved in fibrillary Aβ-induced neurotoxicity. However, the early complement factors already can be detected in earliest stages of AD brain pathology, the diffuse plaques, while the late complement proteins of the membrane complement factor are found in later stages of AD pathology and only in mature plaques with tau positive neurites (Eikelenboom et al., 2006). So, the complement proteins can play a distinct role in the different stages of the pathological cascade in AD brains. In initial stages, the earlier complement factors could be involved in the process of abnormal synapse modulation, while in later stages the full complement activation, including formation of the membrane attack complex, could be involved in Aβ-induced neurotoxicity. This interpretation is in agreement with the findings of Matarin et al., indicating that in the transgenic AD mice models the late, but not the early, immune changes are related to synapse and neuronal loss.

    In conclusion, the transgenic AD mice are interesting models in which to investigate the interactions between immune system-related factors and Aβ deposition in the early pathological stages of AD. Moreover, the transgenic AD models also seem relevant and promising for a better understanding of the role of inflammation in the late-onset form of AD.


    . The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res. 2011 Mar;8(2):142-50. PubMed.

    . Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci. 2006 Apr-May;24(2-3):157-65. PubMed.

    . The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm. 2006 Nov;113(11):1685-95. PubMed.

  5. We thank Dr. Eikelenboom and Dr. Hoozemans for their comment and for pointing out highly relevant studies and reviews confirming that the mouse and human data are so consistent. The different roles of the immune system at different stages of the disease and in relation to plaques versus neurofibrillary tangles will be key to understanding what approaches can be taken for therapy as the disease progresses. This complexity underlines the importance of carefully matching therapeutic agents to the stage of disease progression where they may be effective when planning clinical trials. It is highly likely that an agent that prevents or delays the progression of the early phases of Alzheimer's disease will be ineffective or even damaging at later stages. Poor timing has very likely been an important element in the failure of previous clinical trials and may be particularly important where manipulation of the immune system is concerned.

Make a Comment

To make a comment you must login or register.